Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE0005664809
Fri, 22.11.2024
Evotec SE
Ad hoc: Comment on withdrawn non-binding offer
Hamburg, Germany – Evotec SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ: EVO)
Evotec SE has taken notice of the statement made by Halozyme Therapeutics Inc. on 22 November, stating that it has withdrawn its non-binding proposal to acquire Ev [ … ]
Thu, 14.11.2024
Evotec SE
Ad hoc: Comment on media report
Hamburg, Germany – Evotec SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ: EVO)
With respect to a media report, Evotec SE (“Company”) declares that it has received, without prior contact, a non-binding expression of interest from the listed US biotechnology [ … ]
Wed, 06.11.2024
Evotec SE
Guidance for 2024 confirmed with full-year 2024 revenue and adjusted EBITDA targets on track, despite challenging market conditions
Robust growth of Just - Evotec Biologics driven by roll out of projects together with Sandoz and progress of discovery partnerships
Successful extensions & expansions with BMS and Novo Nordisk; new collaboration [ … ]
Tue, 05.11.2024
Evotec SE
Evotec divests chemical API-focused CDMO operation in Halle/Westphalia (Evotec DS) to Monacum Partners
Transaction aligns with Evotec’s strategic optimization efforts, concentrating resources on key growth drivers
New ownership committed to maintaining and growing the business
Hamburg, 05 November 2024:
Evotec SE (Frankfur [ … ]
Wed, 30.10.2024
Evotec SE
Hamburg, Germany, 30 October 2024:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) will announce its financial results for the first nine months of 2024 on Wednesday, 06 November 2024.
The Company is going to hold a conference call to discuss 9-months results as well as to provide an overview on the ongoing [ … ]
Wed, 23.10.2024
Evotec SE
Key scientific achievements drive the expansion of the pipeline of molecular glue degraders in fields beyond oncology
Evotec receives a US$ 50 m payment from Bristol Myers Squibb; potential programme-based milestone payments contribute to the deal value
Hamburg, Germany, 23 October 2024:
Evotec SE (Frankfurt Stock Exchange: EV [ … ]
Thu, 26.09.2024
Evotec SE
Novo Nordisk will provide funding for technology development activities at Evotec to support clinical and commercial manufacturing of stem cell-based therapies
Hamburg, Germany, 26 September 2024:
Evotec SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced today that Evotec has entered a techn [ … ]
Fri, 20.09.2024
Evotec SE
J.POD® Toulouse, France (EU) brings disruptive, scalable continuous biologics manufacturing technology to the region
Just – Evotec Biologics’ J.POD® technology offers a paradigm shift in biomanufacturing with cost-effective and flexible clinical and commercial supply solutions
Hamburg, Germany, and Toulouse, France, 20 Septemb [ … ]
Fri, 20.09.2024
Evotec SE
J.POD® Toulouse, France (EU) brings disruptive, scalable continuous biologics manufacturing technology to the region
Just – Evotec Biologics’ J.POD® technology offers a paradigm shift in biomanufacturing with cost-effective and flexible clinical and commercial supply solutions
Hamburg, Germany, and Toulouse, France, 20 Septemb [ … ]
Tue, 03.09.2024
Evotec SE
Dr Matthias Evers steps down as Chief Business Officer effective 01 October 2024
Distribution of responsibilities across other Management Board functions
Hamburg, Germany, 03 September 2024:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced that its Chief Business Officer, [ … ]